$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Usage and dosage of tremelimumab/tremelimumab combined with durvalumab
2026-02-01 22:25:32
Check Details
Is tremelimumab/tremelimumab targeted or immunotherapy?
2026-02-01 22:25:32
Check Details
Know the news early: Efficacy and side effects of tremelimumab/tremelimumab
2026-02-01 22:25:32
Check Details
What is Rituximab?
2026-02-01 22:25:32
Check Details
Indications for Rituximab
2026-02-01 22:25:32
Check Details
What are the side effects of Rituximab?
2026-02-01 22:25:32
Check Details
Rituximab (Rituximab) effects and efficacy
2026-02-01 22:25:32
Check Details
Rituximab mechanism of action
2026-02-01 22:25:32
Check Details
Rituximab usage and dosage
2026-02-01 22:25:32
Check Details
How is Rituximab used?
2026-02-01 22:25:32
Check Details
How effective is Rituximab in treating rheumatoid arthritis?
2026-02-01 22:25:32
Check Details
How long does it take for Rituximab to work in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia?
2026-02-01 22:25:32
Check Details
1
2
...
452
453
454
455
456
457
458
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
2
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
3
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
4
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
5
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
6
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
7
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
8
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
9
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
10
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors
11
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
12
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)